Expression of Angiogenesis Regulatory Proteins and Epithelial-Mesenchymal Transition Factors in Platelets of the Breast Cancer Patients

Table 1

Biomarker levels in PP and clinical characteristics.

Groups	Number of patients	PF4 (ng)	TGF- (ng)	VEGF (pg)	PDGF-BB (pg)
Stage
I+II	24	21.6 ± 11.3	16.5 ± 10.6^a	2.37 ± 1.0^a	40.4 ± 13.3^a
III+IV	13	24.4 ± 11.5	24.6 ± 12.2	3.38 ± 1.28	49.9 ± 13.8
Age
>60	8	22.9 ± 11.8	23.1 ± 12.5	2.84 ± 1.12	50.3 ± 14.6
40–60	23	22.3 ± 11.6	20.16 ± 17.4	3.05 ± 1.23	46.3 ± 13.5
<40	6	23.3 ± 12.9	20.8 ± 18.0	2.89 ± 1.11	44.6 ± 13.1
LN status
N0	11	22.1 ± 11.2	16.4 ± 10.1^b	2.32 ± 1.05^b	40.2 ± 13.1^b
N13	26	22.8 ± 12.1	24.5 ± 11.3	3.31 ± 1.14	49.8 ± 13.5
Molecular subtypes
Luminal A	9	21.9 ± 11.7	18.4 ± 11.6^c	2.66 ± 1.09^c	42.8 ± 13.4^c
Luminal B	12	22.1 ± 12.3	19.7 ± 12.9	2.73 ± 1.17	43.2 ± 13.3
HER-2(+)	7	24.9 ± 12.9	28.9 ± 13.7	3.51 ± 1.25	52.1 ± 14.3
Basal like	9	22.2 ± 11.1	33.2 ± 15.2	3.74 ± 1.26	56.2 ± 14.7

Variables are normalized to actin and expressed per 10⁶ platelets. Being constrained by relatively low number of candidates in each clinical subgroup, we used average content instead of median level to make the comparisons. ^aStages I+II versus III+IV: , ^bLN status N0 versus N1-3: , and ^cLuminal A or B versus HER-2 or Basal like: .